Cagrilintide is not approved for any indication anywhere
Last year, the World Health Organization (WHO) issued its first guideline endorsing GLP-1 therapies for the long-term treatment of obesity, recognizing it as a chronic disease and recommending these agents as part of comprehensive management strategies that include diet, physical activity, and structured care
Genetic predisposition can modulate cellular sensitivity to apoptosis, and multiple regulatory factors are involved, including inflammatory mediators (IFN-, IL-2, IL-1), TSH, and anti-TPO antibodies
In a double blinded randomised study, daily injections of semaglutide (0.4 mg) in obese patients resulted in an average of 14% decrease in body weight, over placebo, after a year
The revised guidelines recommend treating all patients with a paracetamol concentration above a single treatment line on the paracetamol nomogram (the 100 milligram (mg) per litre (L) at four hours after overdose treatment line) and treating all patients with a staggered overdose or uncertain time of ingestion [10]
